Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The lancet. Diabetes & endocrinology
- Publicado em
- 22 dez 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial
Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut, Yulia G Pokramovich, Mark E Molitch, Nina Leonova, Gérald Raverot, Elena Grineva et al.
Descritores MeSH
- Acromegaly
- Human Growth Hormone
- Capsules
- Humans
- Insulin-Like Growth Factor I
- Ligands
- Growth Hormone
- Octreotide
- Treatment Outcome
- Receptors, Somatostatin
Veja também
Estudos relacionados
- Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine
- Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
- Medical treatment in acromegaly: a network meta-analysis
- Serum biomarkers of colonic polyps in patients with acromegaly: a meta-analysis and systematic review